NICE TAs

30/07/2026

TA1181: Aficamten for treating symptomatic obstructive hypertrophic cardiomyopathy

16/07/2026

TA1179: Lutetium-177 vipivotide tetraxetan for treating PSMA-positive hormone-relapsed metastatic prostate cancer after an anti-androgen but not a taxane (terminated evaluation)

16/07/2026

TA1180: Netarsudil for treating open-angle glaucoma or ocular hypertension (terminated evaluation)

15/07/2026

TA1178: Deuruxolitinib for treating severe alopecia areata

14/07/2026

TA1177: Pembrolizumab with chemoradiotherapy for untreated locally advanced cervical cancer

09/07/2026

TA1176: Teplizumab for delaying the onset of stage 3 type 1 diabetes in people 8 years and over with stage 2 type 1 diabetes

09/07/2026

TA1175: Glycopyrronium bromide cream for treating severe primary axillary hyperhidrosis

09/07/2026

TA1174: Cemiplimab for treating recurrent or metastatic cervical cancer that has progressed on or after platinum-based chemotherapy

01/07/2026

TA1173: Pirtobrutinib for treating relapsed or refractory chronic lymphocytic leukaemia after a BTK inhibitor

30/06/2026

TA1172: Atogepant for treating migraine

24/06/2026

TA1169: Mirvetuximab soravtansine for treating folate receptor-alpha-positive platinum-resistant epithelial ovarian, fallopian tube or primary peritoneal cancer

24/06/2026

TA1170: Daratumumab with bortezomib, lenalidomide and dexamethasone for untreated multiple myeloma when a stem cell transplant is unsuitable

24/06/2026

TA1171: Seladelpar for previously treated primary biliary cholangitis

18/06/2026

TA1168: Imlunestrant for treating oestrogen receptor-positive HER2-negative advanced breast cancer after endocrine therapy (terminated evaluation)

18/06/2026

TAA1167: Serplulimab with carboplatin and etoposide for untreated extensive-stage small-cell lung cancer

17/06/2026

TA1166: Mepolizumab for maintenance treatment of uncontrolled chronic obstructive pulmonary disease with raised blood eosinophils

16/06/2026

TA1165: Cemiplimab with platinum-based chemotherapy for untreated advanced non-small-cell lung cancer

11/06/2026

TA1164: Tisotumab vedotin for treating recurrent or metastatic cervical cancer that has progressed on or after systemic treatment

TA1163: Nogapendekin alfa inbakicept with BCG for non-muscle-invasive bladder cancer with carcinoma in situ that is unresponsive to BCG (terminated evaluation)

04/06/2026

TA1162: Nusinersen and risdiplam for treating spinal muscular atrophy